You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2025

List of Excipients in API deferiprone


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing deferiprone

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Chiesi USA Inc FERRIPROX deferiprone 10122-100 CELLULOSE, MICROCRYSTALLINE
Chiesi USA Inc FERRIPROX deferiprone 10122-100 HYPROMELLOSE 2910
Chiesi USA Inc FERRIPROX deferiprone 10122-100 MAGNESIUM STEARATE
Chiesi USA Inc FERRIPROX deferiprone 10122-100 POLYETHYLENE GLYCOL 3350
Chiesi USA Inc FERRIPROX deferiprone 10122-100 SILICON DIOXIDE
Chiesi USA Inc FERRIPROX deferiprone 10122-100 TITANIUM DIOXIDE
Chiesi USA Inc FERRIPROX deferiprone 10122-101 FD&C YELLOW NO. 6
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Get Started Free

Excipients in ANDA-approved (generic) drugs containing deferiprone

Company Ingredient NDC Excipient
Hikma Pharmaceuticals USA Inc deferiprone 0054-0576 CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc deferiprone 0054-0576 CROSPOVIDONE
Hikma Pharmaceuticals USA Inc deferiprone 0054-0576 HYPROMELLOSE
Hikma Pharmaceuticals USA Inc deferiprone 0054-0576 MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc deferiprone 0054-0576 POLYETHYLENE GLYCOL 1000
Hikma Pharmaceuticals USA Inc deferiprone 0054-0576 POLYSORBATE 80
Hikma Pharmaceuticals USA Inc deferiprone 0054-0576 SILICON DIOXIDE
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Get Started Free

Detailed excipient profiles for deferiprone

Excipient focus: CELLULOSE, MICROCRYSTALLINE

Excipient focus: CROSPOVIDONE

Excipient focus: FD&C YELLOW NO. 6

Excipient focus: GLYCERIN

Excipient focus: HYDROCHLORIC ACID

Excipient focus: HYDROXYETHYL CELLULOSE

Excipient focus: HYDROXYPROPYL CELLULOSE

Excipient focus: HYPROMELLOSE

Excipient focus: HYPROMELLOSE 2910

Excipient focus: HYPROMELLOSE ACETATE SUCCINATE 06081224

deferiprone drug variants not containing HYPROMELLOSE ACETATE SUCCINATE 06081224

Company Ingredient NDC
Hikma Pharmaceuticals USA Inc deferiprone 0054-0576
Hikma Pharmaceuticals USA Inc deferiprone 0054-0711
Chiesi USA Inc deferiprone 10122-100
Chiesi USA Inc deferiprone 10122-101
Taro Pharmaceuticals USA Inc deferiprone 51672-4196
ApoPharma USA Inc deferiprone 52609-0006
ApoPharma USA Inc deferiprone 52609-0007
>Company >Ingredient >NDC

Subscribe to access the full database, or Get Started Free

Excipient focus: MAGNESIUM OXIDE

Excipient focus: MAGNESIUM STEARATE

Excipient focus: METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER

deferiprone drug variants not containing METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER

Company Ingredient NDC
Hikma Pharmaceuticals USA Inc deferiprone 0054-0576
Hikma Pharmaceuticals USA Inc deferiprone 0054-0711
Chiesi USA Inc deferiprone 10122-100
Chiesi USA Inc deferiprone 10122-101
Taro Pharmaceuticals USA Inc deferiprone 51672-4196
ApoPharma USA Inc deferiprone 52609-0006
ApoPharma USA Inc deferiprone 52609-0007
>Company >Ingredient >NDC

Subscribe to access the full database, or Get Started Free

Excipient focus: METHYLCELLULOSE

Excipient focus: PEPPERMINT OIL

Excipient focus: POLYETHYLENE GLYCOL 1000

Excipient focus: POLYETHYLENE GLYCOL 3350

Excipient focus: POLYETHYLENE GLYCOL 8000

Excipient focus: POLYSORBATE 80

Excipient focus: SILICON DIOXIDE

Excipient focus: SUCRALOSE

Excipient focus: TALC

Excipient focus: TITANIUM DIOXIDE

Excipient focus: TRIETHYL CITRATE

Excipient focus: WATER

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links